1887

Chapter 33 : Molecular Detection of Human Papillomaviruses

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Ebook: Choose a downloadable PDF or ePub file. Chapter is a downloadable PDF file. File must be downloaded within 48 hours of purchase

Buy this Chapter
Digital (?) $30.00

Preview this chapter:
Zoom in
Zoomout

Molecular Detection of Human Papillomaviruses, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555819071/9781555819088.ch33-1.gif /docserver/preview/fulltext/10.1128/9781555819071/9781555819088.ch33-2.gif

Abstract:

The importance of human papillomaviruses (HPVs) in biology and medicine was highlighted by the award of the 2008 Nobel Prize in Medicine to Harald zur Hausen in recognition of his discovery of the oncogenic role of HPV in cervical cancer (1). Numerous international epidemiologic studies confirmed this association, which ultimately led to the successful development of vaccines that prevent HPV infection and tests that provide another tool for cervical cancer control.

Citation: Quigley D, Unger E. 2016. Molecular Detection of Human Papillomaviruses, p 465-475. In Persing D, Tenover F, Hayden R, Ieven M, Miller M, Nolte F, Tang Y, van Belkum A (ed), Molecular Microbiology. ASM Press, Washington, DC. doi: 10.1128/9781555819071.ch33
Highlighted Text: Show | Hide
Loading full text...

Full text loading...

Figures

Image of FIGURE 1
FIGURE 1

Schematic diagram of genomic organization of the open reading frame of human papillomavirus 16. P97 refers to dominant promoter. All papillomaviruses are similar in their genetic organization and appearance by electron microscopy. URR, upstream regulatory region.

Citation: Quigley D, Unger E. 2016. Molecular Detection of Human Papillomaviruses, p 465-475. In Persing D, Tenover F, Hayden R, Ieven M, Miller M, Nolte F, Tang Y, van Belkum A (ed), Molecular Microbiology. ASM Press, Washington, DC. doi: 10.1128/9781555819071.ch33
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 2
FIGURE 2

Phylogenetic tree based on the L1 open reading frame sequences of 170 HPV types, single animal papillomaviruses, and newly identified HPVs using metagenomic sequencing. The maximum likelihood method was used for the analysis and the tree was constructed using the MEGA5.1 program. The numbers at the ends of each of the branches identify an HPV type; m-numbers refer to metagenomics. All other abbreviations refer to animal PV types. The outermost semicircular symbols identify PV genera (e.g., the genus ) The number at the inner semicircular symbol refers to PV species. To give an example taken from the upper part of the figure, the HPV types 33, 58, 67, 52, 31, 16, and 35 together form the HPV species 9 in the genus . Reprinted from de Villiers ( ) with permission of the publisher.

Citation: Quigley D, Unger E. 2016. Molecular Detection of Human Papillomaviruses, p 465-475. In Persing D, Tenover F, Hayden R, Ieven M, Miller M, Nolte F, Tang Y, van Belkum A (ed), Molecular Microbiology. ASM Press, Washington, DC. doi: 10.1128/9781555819071.ch33
Permissions and Reprints Request Permissions
Download as Powerpoint

References

/content/book/10.1128/9781555819071.ch33
1. Pincock S. 2008. Virologist wins Nobel for cervical cancer discovery. Lancet 372:1374[CrossRef].[PubMed]
2. Castellsagué X. 2008. Natural history and epidemiology of HPV infection and cervical cancer. Gynecol Oncol 110(Suppl 2):S4S7[CrossRef].[PubMed]
3. Moscicki AB, Schiffman M, Burchell A, Albero G, Giuliano AR, Goodman MT, Kjaer SK, Palefsky J. 2012. Updating the natural history of human papillomavirus and anogenital cancers. Vaccine 30(Suppl 5):F24F33[CrossRef].[PubMed]
4. Doorbar J, Quint W, Banks L, Bravo IG, Stoler M, Broker TR, Stanley MA. 2012. The biology and life-cycle of human papillomaviruses. Vaccine 30(Suppl 5):F55F70[CrossRef].[PubMed]
5. de Villiers EM. 2013. Cross-roads in the classification of papillomaviruses. Virology 445:210[CrossRef].[PubMed]
6. Bernard HU, Burk RD, Chen Z, van Doorslaer K, zur Hausen H, de Villiers EM. 2010. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology 401:7079[CrossRef].[PubMed]
7. Lambert PF, McBride A, Bernard HU. 2013. Special issue: The Papillomavirus Episteme. Virology 445:1[CrossRef].
8. IARC. 2012. Human papillomaviruses, p 255–313. In IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Biological Agents, vol 100B. IARC, Lyon, France.
9. Combes JD, Guan P, Franceschi S, Clifford GM. 2015. Judging the carcinogenicity of rare human papillomavirus types. Int J Cancer 136:740742.[PubMed]
10. Satterwhite CL, Torrone E, Meites E, Dunne EF, Mahajan R, Ocfemia MC, Su J, Xu F, Weinstock H. 2013. Sexually transmitted infections among US women and men: prevalence and incidence estimates, 2008. Sex Transm Dis 40:187193[CrossRef].[PubMed]
11. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. 1998. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 338:423428[CrossRef].[PubMed]
12. Hariri S, Unger ER, Sternberg M, Dunne EF, Swan D, Patel S, Markowitz LE. 2011. Prevalence of genital human papillomavirus among females in the United States, the National Health And Nutrition Examination Survey, 2003–2006. J Infect Dis 204:566573[CrossRef].[PubMed]
13. Dunne EF, Sternberg M, Markowitz LE, McQuillan G, Swan D, Patel S, Unger ER. 2011. Human papillomavirus (HPV) 6, 11, 16, and 18 prevalence among females in the United States—National Health And Nutrition Examination Survey, 2003–2006: opportunity to measure HPV vaccine impact? J Infect Dis 204:562565[CrossRef].[PubMed]
14. Revzina NV, Diclemente RJ. 2005. Prevalence and incidence of human papillomavirus infection in women in the USA: a systematic review. Int J STD AIDS 16:528537[CrossRef].[PubMed]
15. Dunne EF, Nielson CM, Stone KM, Markowitz LE, Giuliano AR. 2006. Prevalence of HPV infection among men: a systematic review of the literature. J Infect Dis 194:10441057[CrossRef].[PubMed]
16. Snijders PJ, van den Brule AJ, Meijer CJ. 2003. The clinical relevance of human papillomavirus testing: relationship between analytical and clinical sensitivity. J Pathol 201:16[CrossRef].[PubMed]
17. Dillner J. 2013. Primary human papillomavirus testing in organized cervical screening. Curr Opin Obstet Gynecol 25:1116[CrossRef].[PubMed]
18. Cuzick J, Bergeron C, von Knebel Doeberitz M, Gravitt P, Jeronimo J, Lorincz AT,. J L M Meijer C, Sankaranarayanan R, J F Snijders P, Szarewski A. 2012. New technologies and procedures for cervical cancer screening. Vaccine 30(Suppl 5):F107F116.
19. Murphy J, Kennedy EB, Dunn S, McLachlin CM, Fung Kee Fung M, Gzik D, Shier M, Paszat L. 2012. HPV testing in primary cervical screening: a systematic review and meta-analysis. J Obstet Gynaecol Can 34:443452.[PubMed]
20. Rebolj M, Preisler S, Ejegod DM, Rygaard C, Lynge E, Bonde J. 2014. Disagreement between human papillomavirus assays: an unexpected challenge for the choice of an assay in primary cervical screening. PLoS One 9:e86835[CrossRef].[PubMed]
21. Cuzick J, Cadman L, Mesher D, Austin J, Ashdown-Barr L, Ho L, Terry G, Liddle S, Wright C, Lyons D, Szarewski A. 2013. Comparing the performance of six human papillomavirus tests in a screening population. Br J Cancer 108:908913[CrossRef].[PubMed]
22. Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J, Garcia FA, Moriarty AT, Waxman AG, Wilbur DC, Wentzensen N, Downs LS Jr, Spitzer M, Moscicki AB, Franco EL, Stoler MH, Schiffman M, Castle PE, Myers ER, ACS-ASCCP-ASCP Cervical Cancer Guideline Committee. 2012. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin 62:147172[CrossRef].[PubMed]
23. Moyer VA, U.S. Preventive Services Task Force. 2012. Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 156:880891, W312. (Erratum 158:852, 2013.)
24. ACOG Practice Bulletin Number 131: Screening for cervical cancer. 2012. Obstet Gynecol 120:12221238.
25. Perkins RB, Stier EA. 2014. Should U.S. women be screened for cervical cancer with pap tests, HPV tests, or both? Ann Intern Med 161:295297[CrossRef].[PubMed]
26. Gillison ML, Alemany L, Snijders PJ, Chaturvedi A, Steinberg BM, Schwartz S, Castellsagué X. 2012. Human papillomavirus and diseases of the upper airway: head and neck cancer and respiratory papillomatosis. Vaccine 30(Suppl 5):F34F54[CrossRef].[PubMed]
27. D'Souza G, Kreimer AR, Viscidi R, Pawlita M, Fakhry C, Koch WM, Westra WH, Gillison ML. 2007. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 356:19441956[CrossRef].[PubMed]
28. Chaturvedi AK, Engels EA, Pfeiffer RM, Hernandez BY, Xiao W, Kim E, Jiang B, Goodman MT, Sibug-Saber M, Cozen W, Liu L, Lynch CF, Wentzensen N, Jordan RC, Altekruse S, Anderson WF, Rosenberg PS, Gillison ML. 2011. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 29:42944301[CrossRef].[PubMed]
29. Mehanna H, Beech T, Nicholson T, El-Hariry I, McConkey C, Paleri V, Roberts S. 2013. Prevalence of human papillomavirus in oropharyngeal and nonoropharyngeal head and neck cancer—systematic review and meta-analysis of trends by time and region. Head Neck 35:747755[CrossRef].[PubMed]
30. Steinau M, Saraiya M, Goodman MT, Peters ES, Watson M, Cleveland JL, Lynch CF, Wilkinson EJ, Hernandez BY, Copeland G, Saber MS, Hopenhayn C, Huang Y, Cozen W, Lyu C, Unger ER, HPV Typing of Cancers Workgroup. 2014. Human papillomavirus prevalence in oropharyngeal cancer before vaccine introduction, United States. Emerg Infect Dis 20:822828.
31. Gillison ML, D'Souza G, Westra W, Sugar E, Xiao W, Begum S, Viscidi R. 2008. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst 100:407420[CrossRef].[PubMed]
32. Mroz EA, Rocco JW. 2013. MATH, a novel measure of intratumor genetic heterogeneity, is high in poor-outcome classes of head and neck squamous cell carcinoma. Oral Oncol 49:211215[CrossRef].[PubMed]
33. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tân PF, Westra WH, Chung CH, Jordan RC, Lu C, Kim H, Axelrod R, Silverman CC, Redmond KP, Gillison ML. 2010. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 363:2435[CrossRef].[PubMed]
34. Steinau M, Unger ER, Hernandez BY, Goodman MT, Copeland G, Hopenhayn C, Cozen W, Saber MS, Huang Y, Peters ES, Lynch CF, Wilkinson EJ, Rajeevan MS, Lyu C, Saraiya M. 2013. Human papillomavirus prevalence in invasive anal cancers in the United States before vaccine introduction. J Low Genit Tract Dis 17:397403[CrossRef].[PubMed]
35. Nyitray A. 2008. Anal cancer and human papillomaviruses in heterosexual men. Curr Oncol 15:204205[CrossRef].[PubMed]
36. Frisch M, Glimelius B, van den Brule AJ, Wohlfahrt J, Meijer CJ, Walboomers JM, Goldman S, Svensson C, Adami HO, Melbye M. 1997. Sexually transmitted infection as a cause of anal cancer. N Engl J Med 337:13501358[CrossRef].[PubMed]
37. Palefsky JM. 2009. Anal cancer prevention in HIV-positive men and women. Curr Opin Oncol 21:433438[CrossRef].[PubMed]
38. Palefsky JM, Giuliano AR, Goldstone S, Moreira ED Jr, Aranda C, Jessen H, Hillman R, Ferris D, Coutlee F, Stoler MH, Marshall JB, Radley D, Vuocolo S, Haupt RM, Guris D, Garner EI. 2011. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med 365:15761585[CrossRef].[PubMed]
39. National Cancer Institute. 2015. SEER Cancer Statistics Factsheets: Anal Cancer. Surveillance, Epidemiology, and End Results Program, National Cancer Institute, Bethesda, MD. http://seer.cancer.gov/statfacts/html/anus.html.
40. Swedish KA, Lee EQ, Goldstone SE. 2011. The changing picture of high-grade anal intraepithelial neoplasia in men who have sex with men: the effects of 10 years of experience performing high-resolution anoscopy. Dis Colon Rectum 54:10031007[CrossRef].[PubMed]
41. Goldstone SE, Moshier E. 2010. Detection of oncogenic human papillomavirus impacts anal screening guidelines in men who have sex with men. Dis Colon Rectum 53:11351142[CrossRef].[PubMed]
42. Etienney I, Vuong S, Si-Mohamed A, Fléjou JF, Atienza P, Bauer P, Cytological Diaconesses Group. 2012. Value of cytologic Papanicolaou smears and polymerase chain reaction screening for human papillomavirus DNA in detecting anal intraepithelial neoplasia: comparison with histology of a surgical sample. Cancer 118:60316038[CrossRef].[PubMed]
43. Kocken M, Helmerhorst TJ, Berkhof J, Louwers JA, Nobbenhuis MA, Bais AG, Hogewoning CJ, Zaal A, Verheijen RH, Snijders PJ, Meijer CJ. 2011. Risk of recurrent high-grade cervical intraepithelial neoplasia after successful treatment: a long-term multi-cohort study. Lancet Oncol 12:441450[CrossRef].[PubMed]
44. Kocken M, Uijterwaal MH, de Vries AL, Berkhof J, Ket JC, Helmerhorst TJ, Meijer CJ. 2012. High-risk human papillomavirus testing versus cytology in predicting post-treatment disease in women treated for high-grade cervical disease: a systematic review and meta-analysis. Gynecol Oncol 125:500507[CrossRef].[PubMed]
45. Cubie HA, Canham M, Moore C, Pedraza J, Graham C, Cuschieri K. 2014. Evaluation of commercial HPV assays in the context of post-treatment follow-up: Scottish Test of Cure Study (STOCS-H). J Clin Pathol 67:458463[CrossRef].[PubMed]
46. Einstein MH, Smith KM, Davis TE, Schmeler KM, Ferris DG, Savage AH, Gray JE, Stoler MH, Wright TC Jr, Ferenczy A, Castle PE. 2014. Clinical evaluation of the cartridge-based GeneXpert human papillomavirus assay in women referred for colposcopy. J Clin Microbiol 52:20892095[CrossRef].[PubMed]
47. Castle PE, Wheeler CM, Solomon D, Schiffman M, Peyton CL, ALTS Group. 2004. Interlaboratory reliability of Hybrid Capture 2. Am J Clin Pathol 122:238245.
48. Castle PE, Schiffman M, Burk RD, Wacholder S, Hildesheim A, Herrero R, Bratti MC, Sherman ME, Lorincz A. 2002. Restricted cross-reactivity of hybrid capture 2 with nononcogenic human papillomavirus types. Cancer Epidemiol Biomarkers Prev 11:13941399.[PubMed]
49. Peyton CL, Schiffman M, Lörincz AT, Hunt WC, Mielzynska I, Bratti C, Eaton S, Hildesheim A, Morera LA, Rodriguez AC, Herrero R, Sherman ME, Wheeler CM. 1998. Comparison of PCR- and hybrid capture-based human papillomavirus detection systems using multiple cervical specimen collection strategies. J Clin Microbiol 36:32483254.[PubMed]
50. Poljak M, Marin IJ, Seme K, Vince A. 2002. Hybrid Capture II HPV Test detects at least 15 human papillomavirus genotypes not included in its current high-risk probe cocktail. J Clin Virol 25(Suppl 3):S89S97[CrossRef].[PubMed]
51. Sandri MT, Lentati P, Benini E, Dell'Orto P, Zorzino L, Carozzi FM, Maisonneuve P, Passerini R, Salvatici M, Casadio C, Boveri S, Sideri M. 2006. Comparison of the Digene HC2 assay and the Roche AMPLICOR human papillomavirus (HPV) test for detection of high-risk HPV genotypes in cervical samples. J Clin Microbiol 44:21412146[CrossRef].[PubMed]
52. Ginocchio CC, Barth D, Zhang F. 2008. Comparison of the Third Wave Invader human papillomavirus (HPV) assay and the digene HPV hybrid capture 2 assay for detection of high-risk HPV DNA. J Clin Microbiol 46:16411646[CrossRef].[PubMed]
53. Schutzbank TE, Jarvis C, Kahmann N, Lopez K, Weimer M, Yount A. 2007. Detection of high-risk papillomavirus DNA with commercial invader-technology-based analyte-specific reagents following automated extraction of DNA from cervical brushings in ThinPrep media. J Clin Microbiol 45:40674069[CrossRef].[PubMed]
54. Nolte FS, Ribeiro-Nesbitt DG. 2014. Comparison of the Aptima and Cervista tests for detection of high-risk human papillomavirus in cervical cytology specimens. Am J Clin Pathol 142:561566[CrossRef].[PubMed]
55. Stoler MH, Wright TC Jr, Sharma A, Apple R, Gutekunst K, Wright TL, ATHENA (Addressing THE Need for Advanced HPV Diagnostics) HPV Study Group. 2011. High-risk human papillomavirus testing in women with ASC-US cytology: results from the ATHENA HPV study. Am J Clin Pathol 135:468475.
56. de Sanjose S, , et al, Retrospective International Survey and HPV Time Trends Study Group. 2010. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 11:10481056[CrossRef].[PubMed]
57. Szarewski A, Mesher D, Cadman L, Austin J, Ashdown-Barr L, Ho L, Terry G, Liddle S, Young M, Stoler M, McCarthy J, Wright C, Bergeron C, Soutter WP, Lyons D, Cuzick J. 2012. Comparison of seven tests for high-grade cervical intraepithelial neoplasia in women with abnormal smears: the Predictors 2 study. J Clin Microbiol 50:18671873[CrossRef].[PubMed]
58. Szarewski A, Ambroisine L, Cadman L, Austin J, Ho L, Terry G, Liddle S, Dina R, McCarthy J, Buckley H, Bergeron C, Soutter P, Lyons D, Cuzick J. 2008. Comparison of predictors for high-grade cervical intraepithelial neoplasia in women with abnormal smears. Cancer Epidemiol Biomarkers Prev 17:30333042[CrossRef].[PubMed]
59. Cuschieri K, Hardie A, Hovland S, Hoaas B, Karlsen F, Cubie H. 2013. Comparison of the sensitivities of three commercial assays for detection of the high risk HPV types 16, 18 and 45. J Virol Methods 193:147150[CrossRef].[PubMed]
60. Wright TC Jr, Stoler MH, Agreda PM, Beitman GH, Gutierrez EC, Harris JM, Koch KR, Kuebler M, LaViers WD, Legendre BL Jr, Leitch SV, Maus CE, McMillian RA, Nussbaumer WA, Palmer ML, Porter MJ, Richart GA, Schwab RJ, Vaughan LM. 2014. Clinical performance of the BD Onclarity HPV assay using an adjudicated cohort of BD SurePath liquid-based cytology specimens. Am J Clin Pathol 142:4350[CrossRef].[PubMed]
61. Molden T, Kraus I, Karlsen F, Skomedal H, Nygård JF, Hagmar B. 2005. Comparison of human papillomavirus messenger RNA and DNA detection: a cross-sectional study of 4,136 women >30 years of age with a 2-year follow-up of high-grade squamous intraepithelial lesion. Cancer Epidemiol Biomarkers Prev 14:367372[CrossRef].[PubMed]
62. Molden T, Kraus I, Skomedal H, Nordstrøm T, Karlsen F. 2007. PreTect HPV-Proofer: real-time detection and typing of E6/E7 mRNA from carcinogenic human papillomaviruses. J Virol Methods 142:204212[CrossRef].[PubMed]
63. Bergeron C, Ronco G, Reuschenbach M, Wentzensen N, Arbyn M, Stoler M, von Knebel Doeberitz M. 2015. The clinical impact of using p16(INK4a) immunochemistry in cervical histopathology and cytology: an update of recent developments. Int J Cancer 136:27412751[CrossRef].[PubMed]
64. Steenbergen RD, Snijders PJ, Heideman DA, Meijer CJ. 2014. Clinical implications of (epi)genetic changes in HPV-induced cervical precancerous lesions. Nat Rev Cancer 14:395405[CrossRef].[PubMed]
65. Giuliano AR, Papenfuss M, Abrahamsen M, Denman C, de Zapien JG, Henze JL, Ortega L, Brown de Galaz EM, Stephan J, Feng J, Baldwin S, Garcia F, Hatch K. 2001. Human papillomavirus infection at the United States-Mexico border: implications for cervical cancer prevention and control. Cancer Epidemiol Biomarkers Prev 10:11291136.[PubMed]
66. Kulasingam SL, Hughes JP, Kiviat NB, Mao C, Weiss NS, Kuypers JM, Koutsky LA. 2002. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral. JAMA 288:17491757[CrossRef].[PubMed]
67. Peyton CL, Gravitt PE, Hunt WC, Hundley RS, Zhao M, Apple RJ, Wheeler CM. 2001. Determinants of genital human papillomavirus detection in a US population. J Infect Dis 183:15541564[CrossRef].[PubMed]
68. Castle PE, Fetterman B, Poitras N, Lorey T, Shaber R, Kinney W. 2009. Five-year experience of human papillomavirus DNA and Papanicolaou test cotesting. Obstet Gynecol 113:595600[CrossRef].[PubMed]
69. Wilkinson DE, Baylis SA, Padley D, Heath AB, Ferguson M, Pagliusi SR, Quint WG, Wheeler CM, Collaborative Study Group. 2010. Establishment of the 1st World Health Organization international standards for human papillomavirus type 16 DNA and type 18 DNA. Int J Cancer 126:29692983.[PubMed]
70. Tatsas AD, Phelan DF, Gravitt PE, Boitnott JK, Clark DP. 2012. Practice patterns in cervical cancer screening and human papillomavirus testing. Am J Clin Pathol 138:223229[CrossRef].[PubMed]
71. Markowitz LE, Dunne EF, Saraiya M, Chesson HW, Curtis CR, Gee J, Bocchini JA Jr, Unger ER, Centers for Disease Control and Prevention (CDC). 2014. Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 63(RR-05):130.[PubMed].
72. Petrosky E, Bocchini JA, Hariri S, Chesson H, Curtis CR, Saraiya M, Unger ER, Markowitz LE. 2015. Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the Advisory Committee on Immunization Practices. MMWR 64:300304.
73. Saraiya M, Unger ER, Thompson TD, Lynch CF, Hernandez BY, Lyu CW, Steinau M, Watson M, Wilkinson EJ, Hopenhayn C, Copelnad G, Cozen W, Peters ES, Huang Y, Saber MS, Altekruse S, Goodman MT, HPV Typing of Cancers Workgroup. 2015. US assessment of HPV types in cancers: implications for current and 9-valent vaccines. J Natl Cancer Inst 107:djv086.
74. Wong CA, Saraiya M, Hariri S, Eckert L, Howlett RI, Markowitz LE, Brotherton JM, Sinka K, Martinez-Montañez OG, Kjaer SK, Dunne EF. 2011. Approaches to monitoring biological outcomes for HPV vaccination: challenges of early adopter countries. Vaccine 29:878885[CrossRef].[PubMed]
75. Dillner J, Arbyn M, Unger E, Dillner L. 2011. Monitoring of human papillomavirus vaccination. Clin Exp Immunol 163:1725[CrossRef].[PubMed]
76. Stokley S, Jeyarajah J, Yankey D, Cano M, Gee J, Roark J, Curtis RC, Markowitz L, Immunization Services Division, National Center for Immunization and Respiratory Diseases, CDC, Centers for Disease Control and Prevention (CDC). 2014. Human papillomavirus vaccination coverage among adolescents, 2007–2013, and postlicensure vaccine safety monitoring, 2006–2014—United States. MMWR Morb Mortal Wkly Rep 63:620624.[PubMed]
77. Markowitz LE, Hariri S, Lin C, Dunne EF, Steinau M, McQuillan G, Unger ER. 2013. Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003–2010. J Infect Dis 208:385393[CrossRef].[PubMed]
78. Flagg EW, Schwartz R, Weinstock H. 2013. Prevalence of anogenital warts among participants in private health plans in the United States, 2003–2010: potential impact of human papillomavirus vaccination. Am J Public Health 103:14281435[CrossRef].[PubMed]
79. Powell SE, Hariri S, Steinau M, Bauer HM, Bennett NM, Bloch KC, Niccolai LM, Schafer S, Unger ER, Markowitz LE. 2012. Impact of human papillomavirus (HPV) vaccination on HPV 16/18-related prevalence in precancerous cervical lesions. Vaccine 31:109113[CrossRef].[PubMed]
80. Franco EL, Cuzick J, Hildesheim A, de Sanjosé S. 2006. Chapter 20: issues in planning cervical cancer screening in the era of HPV vaccination. Vaccine 24(Suppl 3):S3/171177.

Tables

Generic image for table
TABLE 1

Summary of clinical tests for high-risk human papillomavirus detection discussed in this chapter

Citation: Quigley D, Unger E. 2016. Molecular Detection of Human Papillomaviruses, p 465-475. In Persing D, Tenover F, Hayden R, Ieven M, Miller M, Nolte F, Tang Y, van Belkum A (ed), Molecular Microbiology. ASM Press, Washington, DC. doi: 10.1128/9781555819071.ch33

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error